Iterum Therapeutics PLC

NASDAQ ITRM

Data sourced from iex and EODHD
Download Data

Iterum Therapeutics PLC Enterprise Value (EV) on June 03, 2024: USD 25.92 M

Iterum Therapeutics PLC Enterprise Value (EV) is USD 25.92 M on June 03, 2024, a NA change year over year. Enterprise Value is a measure of a company's total value, including both its equity and debt. It represents the theoretical takeover price of a company and is often used in valuation methods. Enterprise value is calculated as the sum of a company's market capitalization, total debt, and subtracting its cash and short-term investments.
  • Iterum Therapeutics PLC 52-week high Enterprise Value (EV) is USD 27.41 M on May 13, 2024, which is 5.75% above the current Enterprise Value (EV).
  • Iterum Therapeutics PLC 52-week low Enterprise Value (EV) is USD -210.03 K on February 29, 2024, which is -100.81% below the current Enterprise Value (EV).
  • Iterum Therapeutics PLC average Enterprise Value (EV) for the last 52 weeks is USD 15.44 M.
NASDAQ: ITRM

Iterum Therapeutics PLC

CEO Mr. Corey N. Fishman
IPO Date May 25, 2018
Location Ireland
Headquarters Fitzwilliam Court, Dublin, Ireland, 2
Employees 14
Sector Healthcare
Industry Biotechnology
Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Similar companies

HOTH

Hoth Therapeutics Inc

NA

NA

StockViz Staff

September 16, 2024

Any question? Send us an email